ENOSIS MASTICHOPARAGOGON CHIOU

Their core work

The Chios Mastic Gum Growers' Association (CMGA) is the official representative body for producers of mastiha — a natural resin with Protected Designation of Origin status harvested exclusively in southern Chios, Greece, making it one of the most geographically unique agricultural products in Europe. In EU research projects, they function as the indispensable industry anchor: supplying authenticated raw material, contributing proprietary production knowledge, and ensuring research outputs remain grounded in real-world agricultural and commercial realities. Their two H2020 participations focus on extracting scientific value from mastiha and related aromatic plant by-products — both for clinical health applications (treatment of liver disease in obese patients) and for cosmeceutical and food supplement development. Any researcher or company working with natural plant resins, Mediterranean botanical ingredients, or functional food bioactives will find in CMGA an access point to a controlled, traceable, PDO-certified supply chain that cannot be replicated elsewhere.

What they specialise in

How they've shifted over time

Both H2020 projects began in 2016 and ran through 2020, meaning there is no meaningful temporal split within the dataset — CMGA entered EU research on two simultaneous fronts rather than progressing sequentially. The early (and only) keyword cluster — natural products, phytochemistry, essential oils by-products, eco-friendly technologies — maps entirely to EXANDAS, while MAST4HEALTH carried no extractable keywords, suggesting a more clinical and less keyword-driven research track. What can be inferred is that CMGA pursued a deliberate dual strategy from the outset: one project aimed at commercial product development (cosmeceuticals, food supplements), the other at clinical validation of mastiha's health properties, which is a sophisticated two-track approach for a producer association of this size.

With no H2020 projects beyond 2016, directional movement cannot be determined from EU data alone, but the combination of cosmeceutical and clinical research tracks suggests CMGA is building a scientific evidence base to support premium market positioning for mastiha-derived ingredients.

How they like to work

CMGA participates exclusively as a consortium partner and has never taken a coordinator role across either project — consistent with an industry association that provides material supply, sectoral access, and practical knowledge rather than scientific leadership. Both projects use the MSCA-RISE scheme, which involves staff exchanges between academic and industry partners, meaning CMGA has experience hosting visiting researchers and embedding its own people in university environments. With 25 distinct partners across 12 countries from just two projects, they operate in broad, internationally diverse consortia rather than tight bilateral arrangements.

CMGA has worked with 25 unique consortium partners across 12 countries — a notably wide network for an organisation with only two projects, reflecting the multi-partner structure typical of MSCA-RISE grants. Their geographic reach spans at minimum southern Europe, with likely partners in the Mediterranean, northern Europe, and possibly non-EU associated countries given RISE's international exchange design.

What sets them apart

CMGA holds a positioning that no other organisation in Europe can replicate: they are the sole institutional representative of the world's only producers of PDO-certified mastiha, a resin harvested exclusively in a defined zone of Chios island. For any research consortium needing authenticated, traceable, legally protected botanical material from a Mediterranean source, CMGA is not one option among many — they are the only option. Beyond raw material access, they bring commercial market knowledge, grower networks, and regulatory familiarity with PDO products that academic or industrial partners simply cannot substitute.

Highlights from their portfolio

• MAST4HEALTH
  The largest single grant (EUR 297,000) and the most commercially significant: it builds a clinical evidence base for mastiha as a treatment for NAFLD in obese patients, which — if validated — would open a regulated health claims pathway for one of Greece's most iconic agricultural exports.
• EXANDAS
  Demonstrates CMGA's strategic interest in turning agricultural waste streams (essential oil by-products) into high-value cosmeceutical and nutraceutical ingredients, a strong circular-economy angle with direct commercial application.